<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="24954">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01771614</url>
  </required_header>
  <id_info>
    <org_study_id>Glucotox-2</org_study_id>
    <nct_id>NCT01771614</nct_id>
  </id_info>
  <brief_title>Acute Exercise and Glucotoxicity</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <authority>Denmark: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The effects of exercise on glucotoxicity will be determined in healthy subjects.
      Experimental hyperglycemia will be induced via a constant- or fluctuating-rate glucose
      infusion to establish different patterns of glycemic variability. The outcomes of
      hyperglycemia will be determined by measuring pancreatic endocrine function, insulin
      sensitivity, endothelial function, and oxidative stress.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2013</start_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Pancreatic endocrine function</measure>
    <time_frame>0, 8, and 24 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>The plasma insulin, C-peptide, and glucagon responses to a 0.33 g/kg intravenous glucose tolerance test (IVGTT) will be measured. In each trial, the IVGTT will be performed at 0, 8 and 24 hours.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulin sensitivity</measure>
    <time_frame>0, 8, and 24 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Insulin sensitivity will be measured during an IVGTT in each trial at 0, 8, and 24 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endothelial function</measure>
    <time_frame>0, 2, 4, 6, 8, and 24 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood flow and flow-mediated dilation by Doppler ultrasound will be measured in each trial at 0, 2, 4, 6, 8, and 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxidative stress</measure>
    <time_frame>24 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Urine will be collected over the whole 24-hour period of each trial and 8-iso Prostaglandin F3Î± will be measured.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Type 1 Diabetes</condition>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Rest + Steady-State Hyperglycemia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A T = -1 hours, a 1-hour period of rest will begin. At T = 0 h, an 8-hour period of hyperglycemia will begin. Steady-state hyperglycemia will be induced via a constant infusion rate of glucose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rest + Fluctuating Hyperglycemia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A T = -1 hours, a 1-hour period of rest will begin. At T = 0 h, an 8-hour period of hyperglycemia will begin. Fluctuating hyperglycemia will be induced via a variable infusion rate of glucose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exercise + Steady-State Hyperglycemia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A T = -1 hours, a 1-hour exercise bout will begin. At T = 0 h, an 8-hour period of hyperglycemia will begin. Steady-state hyperglycemia will be induced via a constant infusion rate of glucose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exercise + Fluctuating Hyperglycemia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A T = -1 hours, a 1-hour exercise bout will begin. At T = 0 h, an 8-hour period of hyperglycemia will begin. Fluctuating hyperglycemia will be induced via a variable infusion rate of glucose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Exercise</intervention_name>
    <arm_group_label>Exercise + Steady-State Hyperglycemia</arm_group_label>
    <arm_group_label>Exercise + Fluctuating Hyperglycemia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hyperglycemia</intervention_name>
    <arm_group_label>Rest + Steady-State Hyperglycemia</arm_group_label>
    <arm_group_label>Rest + Fluctuating Hyperglycemia</arm_group_label>
    <arm_group_label>Exercise + Steady-State Hyperglycemia</arm_group_label>
    <arm_group_label>Exercise + Fluctuating Hyperglycemia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-60 years old

          -  BMI 20-35 kg/m2

          -  Willingness to partake in an exercise bout

        Exclusion Criteria:

          -  Contraindication to strenuous exercise

          -  Clinical signs of chronic pulmonary, renal, hepatic, hematological, intestinal, or
             cardiovascular disease

          -  Pregnancy

          -  Smoking

          -  Recent weight loss (&gt;2kg in 6 months)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas P Solomon, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thomas P Solomon, PhD</last_name>
    <phone>+4535457629</phone>
    <email>thomas.solomon@inflammation-metabolism.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <state>Capital Region</state>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas P Solomon, PhD</last_name>
      <phone>+4535457629</phone>
      <email>thomas.solomon@inflammation-metabolism.dk</email>
    </contact>
    <investigator>
      <last_name>Thomas P Solomon, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kristian Karstoft, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sine H Knudsen, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 16, 2013</lastchanged_date>
  <firstreceived_date>January 16, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Thomas Solomon</investigator_full_name>
    <investigator_title>Senior Researcher</investigator_title>
  </responsible_party>
  <keyword>Glucotoxicity</keyword>
  <keyword>Exercise</keyword>
  <keyword>Beta-cell function</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
